Caplin Point Laboratories
NSE: CAPLIPOINT · ISIN INE475E01026 · Healthcare
₹2,527.90+70.70 (+2.88%)
Monday 9 November, 12:04 IST. Delayed. Source: Yahoo Finance.
Price chart
₹2,527.90 +70.70 (+2.88%) today
The day
- Previous close
- ₹2,457.20
- Open
- ₹2,462.00
- Day high
- ₹2,597.50
- Day low
- ₹2,457.00
Listed on NSE since 23 June 2014.
Key numbers
- Market value
- ₹18,110 Cr
- P/E (trailing)
- 27.30
- EPS (trailing)
- ₹87.28
- Price to book
- 5.16
- Dividend yield
- 0.34%
- Debt to equity
- 0.00
- Profit margin
- 29.1%
- Beta
- 0.46
- Volume today
- 1.72 L
- Average volume
- 1.79 L
Source: Yahoo Finance. Ratios use the latest reported (trailing twelve-month) figures.
Revenue and profit
| Year | Revenue | Net profit |
|---|---|---|
| FY23 | ₹1,453.82 Cr | ₹376.26 Cr |
| FY24 | ₹1,679.55 Cr | ₹457.08 Cr |
| FY25 | ₹1,921.23 Cr | ₹536.31 Cr |
| FY26 | ₹2,171.38 Cr | ₹641.24 Cr |
Source: Yahoo Finance, from annual reports. Consolidated where reported.
Quarterly results
| Quarter | Revenue | Net profit | Profit vs year ago |
|---|---|---|---|
| Q1 FY27Apr–Jun 2026 | ₹610 Cr | ₹177 Cr | +15.8% |
| Q4 FY26Jan–Mar 2026Audited | ₹600 Cr | ₹170 Cr | +20.8% |
| Q3 FY26Oct–Dec 2025 | ₹543 Cr | ₹164 Cr | – |
| Q2 FY26Jul–Sep 2025 | ₹534 Cr | ₹154 Cr | – |
| Q1 FY26Apr–Jun 2025 | ₹510 Cr | ₹153 Cr | – |
| Q4 FY25Jan–Mar 2025Audited | ₹502 Cr | ₹141 Cr | – |
Source: Caplin Point Laboratories’s results filed with NSE, consolidated (the whole group). Net profit is the share of Caplin Point Laboratories’s own shareholders where the filing separates it. Profit vs year ago compares with the same quarter a year earlier; – where that quarter is not on file or made a loss.
Download results (zip) A spreadsheet of the quarterly results and balance sheets, with the original filings from NSE.
Balance sheet
| As on | March 2026 | September 2025 |
|---|---|---|
| Fixed assets | ₹756 Cr | ₹700 Cr |
| Investments | ₹859 Cr | ₹636 Cr |
| Inventories | ₹429 Cr | ₹329 Cr |
| Owed by customers | ₹826 Cr | ₹694 Cr |
| Cash and equivalents | ₹94 Cr | ₹108 Cr |
| Total assets | ₹4,045 Cr | ₹3,504 Cr |
| Borrowings | ₹57.00 L | ₹49.00 L |
| Total liabilities | ₹415 Cr | ₹305 Cr |
| Shareholders’ equity | ₹3,586 Cr | ₹3,159 Cr |
Source: Caplin Point Laboratories’s half-yearly statements of assets and liabilities filed with NSE, consolidated. Companies file these every September and March.
About Caplin Point Laboratories
Caplin Point Laboratories Limited, together with its subsidiaries, engages in the development, production, marketing, and export of generic formulations and branded products in India. The company provides tablets, capsules, injections, ophthalmic, liquid orals, softgel, capsules, ointments, creams and gels, powder for injections, suppositories, ovules, pre-mix bag, inhalers, and sprays and IV infusion. It also provides dry and syrups, lyophilized vials, prefilled syringes, emulsion injection, ophthalmic droppers, sachets, liquid injectables, topicals, pre-filled syringes, and pre-mix bags. Caplin Point Laboratories Limited was incorporated in 1990 and is headquartered in Chennai, India.
- Industry
- Drug Manufacturers - Specialty & Generic
- Based in
- Chennai
- Employees
- 4,199
Company website · Profile: Yahoo Finance
In the news
All newsNo headlines name Caplin Point Laboratories in the last day or two.
Dividends and corporate actions
All companies- Dividend - Rs 4 Per Share
Dividend · ex-date 18 September 2026
- Interim Dividend - Rs 4 Per Share
Dividend · ex-date 29 May 2026 · record date 30 May 2026
- Dividend - Rs 3 Per Share
Dividend · ex-date 12 September 2025
- Interim Dividend - Rs 3 Per Share
Dividend · ex-date 30 May 2025
- Annual General Meeting
Action · ex-date 23 September 2024
- Dividend - Rs 2.50 Per Share
Dividend · ex-date 23 September 2024
- Interim Dividend - Rs 2.50 Per Share
Dividend · ex-date 31 May 2024
- Annual General Meeting/Dividend - Rs 2.50 Per Share
Dividend · ex-date 14 September 2023
Source: NSE. Latest first, 8 of 20.
Information only, not investment advice. Prices are delayed.